KeyMed Biosciences Inc
HKEX:2162
| US |
|
Fubotv Inc
NYSE:FUBO
|
Media
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
C
|
C3.ai Inc
NYSE:AI
|
Technology
|
| US |
|
Uber Technologies Inc
NYSE:UBER
|
Road & Rail
|
| CN |
|
NIO Inc
NYSE:NIO
|
Automobiles
|
| US |
|
Fluor Corp
NYSE:FLR
|
Construction
|
| US |
|
Jacobs Engineering Group Inc
NYSE:J
|
Professional Services
|
| US |
|
TopBuild Corp
NYSE:BLD
|
Consumer products
|
| US |
|
Abbott Laboratories
NYSE:ABT
|
Health Care
|
| US |
|
Chevron Corp
NYSE:CVX
|
Energy
|
| US |
|
Occidental Petroleum Corp
NYSE:OXY
|
Energy
|
| US |
|
Matrix Service Co
NASDAQ:MTRX
|
Construction
|
| US |
|
Automatic Data Processing Inc
NASDAQ:ADP
|
Technology
|
| US |
|
Qualcomm Inc
NASDAQ:QCOM
|
Semiconductors
|
| US |
|
Ambarella Inc
NASDAQ:AMBA
|
Semiconductors
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
27.45
56.8
|
| Price Target |
|
We'll email you a reminder when the closing price reaches HKD.
Choose the stock you wish to monitor with a price alert.
|
|
Fubotv Inc
NYSE:FUBO
|
US |
|
|
Bank of America Corp
NYSE:BAC
|
US |
|
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
C
|
C3.ai Inc
NYSE:AI
|
US |
|
|
Uber Technologies Inc
NYSE:UBER
|
US |
|
|
NIO Inc
NYSE:NIO
|
CN |
|
|
Fluor Corp
NYSE:FLR
|
US |
|
|
Jacobs Engineering Group Inc
NYSE:J
|
US |
|
|
TopBuild Corp
NYSE:BLD
|
US |
|
|
Abbott Laboratories
NYSE:ABT
|
US |
|
|
Chevron Corp
NYSE:CVX
|
US |
|
|
Occidental Petroleum Corp
NYSE:OXY
|
US |
|
|
Matrix Service Co
NASDAQ:MTRX
|
US |
|
|
Automatic Data Processing Inc
NASDAQ:ADP
|
US |
|
|
Qualcomm Inc
NASDAQ:QCOM
|
US |
|
|
Ambarella Inc
NASDAQ:AMBA
|
US |
This alert will be permanently deleted.
KeyMed Biosciences Inc
Total Equity
KeyMed Biosciences Inc
Total Equity Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Total Equity | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
K
|
KeyMed Biosciences Inc
HKEX:2162
|
Total Equity
¥3B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Beigene Ltd
HKEX:6160
|
Total Equity
¥25.1B
|
CAGR 3-Years
0%
|
CAGR 5-Years
16%
|
CAGR 10-Years
N/A
|
|
|
Beijing Wantai Biological Pharmacy Enterprise Co Ltd
SSE:603392
|
Total Equity
¥12.7B
|
CAGR 3-Years
71%
|
CAGR 5-Years
57%
|
CAGR 10-Years
N/A
|
|
|
Shanghai RAAS Blood Products Co Ltd
SZSE:002252
|
Total Equity
¥30.7B
|
CAGR 3-Years
6%
|
CAGR 5-Years
22%
|
CAGR 10-Years
24%
|
|
|
Chongqing Zhifei Biological Products Co Ltd
SZSE:300122
|
Total Equity
¥31.5B
|
CAGR 3-Years
32%
|
CAGR 5-Years
47%
|
CAGR 10-Years
29%
|
|
|
Imeik Technology Development Co Ltd
SZSE:300896
|
Total Equity
¥6.3B
|
CAGR 3-Years
12%
|
CAGR 5-Years
74%
|
CAGR 10-Years
N/A
|
|
KeyMed Biosciences Inc
Glance View
Keymed Biosciences, Inc. is an investment holding company. The company is headquartered in Chengdu, Sichuan. The company went IPO on 2021-07-08. The firm focuses on the independent discovery and development of innovative biological therapies that address underserved medical needs in the autoimmune and oncology therapeutic areas. The firm has mastered in-house drug discovery and development technologies, including an innovative antibody discovery platform and a proprietary novel T cell engager (nTCE) bispecific antibody platform. The firm has also established a fully integrated platform covering the key functions of biopharmaceutical development. The firm's main products include CM310, CM326 and CMG901.
See Also
What is KeyMed Biosciences Inc's Total Equity?
Total Equity
3B
CNY
Based on the financial report for Dec 31, 2023, KeyMed Biosciences Inc's Total Equity amounts to 3B CNY.
What is KeyMed Biosciences Inc's Total Equity growth rate?
Total Equity CAGR 1Y
-11%
Over the last year, the Total Equity growth was -11%.
You don't have any saved screeners yet
